OS Therapies Incorporated
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| OSTX | 6OP.F | HBP.TO | MREO | ONCY | APLM | |
|---|---|---|---|---|---|---|
| Market cap | 53.83M | 42.99M | 70.27M | 48.40M | 55.70M | 55.38M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 3.3 | — | -8.4 | -13.1 | -2.1 | -29.2 |
| Price/book | -4.4 | 1.4 | 4.8 | 1.7 | -8.7 | -12.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −35.56% | −66.91% | −54.68% | −82.78% | −58.42% | +71.38% |
| Today | −0.86% | −2.85% | 0.00% | +4.16% | +8.92% | −8.83% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All OSTX news ›OS Therapies CFO reports 20,000-share trust holding
Francis Knuettel II may be deemed a beneficial owner but disclaims ownership except for his pecuniary interest. The entry is dated September 29, 2026. - [Form 3] OS Therapies Inc Initial Statement of Beneficial Ownership OS Therapies CFO…
OS Therapies appoints Frank Knuettel II as CFO
Polar Power Completes Phase 1 of Strategic Restructuring, Reducing Annualized Costs by More Than $1 Million RITZ® Brand Introduces Gluten Free Crackers in Original Flavor OS Therapies reports over $3 million in VAT refund capital received…
OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million
3 E Network Signs Core 9 MVA Power Distribution Agreement for Mikkeli AI Compute Center in Finland Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and…
Rubenstein Public Relations Named Agency of Record for OS Therapies
The Manila Times Rubenstein Public Relations Named Agency of Record for OS Therapies Clinical-Stage Oncology Company Taps RPR to Drive Global Communications as Groundbreaking Cancer Immunotherapy Advances Toward Approval NEW YORK,
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
BioSpace OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treate
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net4
- manilatimes.net1
- newsfilecorp.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.